Next Article in Journal
Comment on “Clinical Features and Course of Brain Metastases in Colorectal Cancer: An Experience from a Single Institution”
Previous Article in Journal
Spontaneous Regression of Metastatic Melanoma after Inoculation with Tetanus–Diphtheria–Pertussis Vaccine
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 3
10.3747/co.20.1266
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma

by
C.W. Hong
1,2,
S.K. Libutti
3,4 and
B.J. Wood
1,4,*
1
Center for Interventional Oncology, Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
2
Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44106, USA
3
Montefiore–Einstein Center for Cancer Care, Department of Surgery, Albert Einstein College of Medicine, Bronx, NY 10467, USA
4
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(3), 274-277; https://doi.org/10.3747/co.20.1266
Submission received: 2 March 2013 / Revised: 5 April 2013 / Accepted: 7 May 2013 / Published: 1 June 2013

Abstract

Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, RFA for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during RFA is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a HCC in a patient who underwent liver transplantation 79 days later.
Keywords: RFA; ablation; hepatocellular carcinoma; doxorubicin; liposomes RFA; ablation; hepatocellular carcinoma; doxorubicin; liposomes

Share and Cite

MDPI and ACS Style

Hong, C.W.; Libutti, S.K.; Wood, B.J. Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma. Curr. Oncol. 2013, 20, 274-277. https://doi.org/10.3747/co.20.1266

AMA Style

Hong CW, Libutti SK, Wood BJ. Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma. Current Oncology. 2013; 20(3):274-277. https://doi.org/10.3747/co.20.1266

Chicago/Turabian Style

Hong, C.W., S.K. Libutti, and B.J. Wood. 2013. "Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma" Current Oncology 20, no. 3: 274-277. https://doi.org/10.3747/co.20.1266

APA Style

Hong, C. W., Libutti, S. K., & Wood, B. J. (2013). Liposomal Doxorubicin Plus Radiofrequency Ablation for Complete Necrosis of a Hepatocellular Carcinoma. Current Oncology, 20(3), 274-277. https://doi.org/10.3747/co.20.1266

Article Metrics

Back to TopTop